MétaCan
Menu
Back to cohort
Record W4402319922 · doi:10.5489/cuaj.8973

NS-AUA 2024 Annual Meeting Abstracts – Best Practices, Benign Disease

2024· article· en· W4402319922 on OpenAlexvenueno aff
Editor CUAJ

Bibliographic record

VenueCanadian Urological Association Journal · 2024
Typearticle
Languageen
FieldMedicine
TopicHematological disorders and diagnostics
Canadian institutionsnot available
Fundersnot available
KeywordsMedicine

Abstract

fetched live from OpenAlex

Introduction: Patients electing benign prostatic hyperplasia (BPH) surgery may wish to cease BPH medical therapy, though some patients may continue or begin medication post-surgery to treat residual symptoms.In this large-scale healthcare claims analysis, we produce rates of continued and de novo BPH medical therapy following transurethral resection of the prostate (TURP), GreenLight photoselective vaporization (PVP), and UroLift prostatic urethral life (PUL) procedures.Methods: Patients with ≥1 year of followup who underwent outpatient TURP (n=20 319), GreenLight (n=10 517), or PUL (n=5793) were identified within this representative sample of 2015-2021 Medicare and commercial claims.Linking pharmaceutical claims to outpatient surgical claims produced rates of continuous and de novo use of alpha-blockers, 5ARI, or combination therapy; only patients with ≥2 instances of medical therapy prescriptions following BPH surgery were included.Perioperative medication usage was defined as ≥2 medication prescriptions within three months only and not beyond; prolonged use was assessed through one and five years postoperative.Results: Rates of perioperative medical therapy were similar between all treatments.The rates of continued medication use following PUL, TURP, and PVP were 2.5%, 4.0% and 4.2%, respectively.De novo use was low after all therapies; lowest for PUL (0.5%) and similar between TURP (0.9%) and PVP (1.0%).The total one-year medical therapy rate was lowest for PUL (3.9%, TURP 6.1%, PVP 6.5%).Rates of continued and de novo use were: PUL (8.4% continued, 1.0% de novo), TURP (7.0% continued, 2.0% de novo), and PVP (7.2% continued, 1.7% de novo).The total combined five-year medical therapy rate was similar between all three therapies: PUL (10.3%),TURP (10.2%), and PVP (10.2%).Alpha-blockers were the leading BPH drug class utilized through one and five years post-PUL, TURP, and PVP.Conclusions: Post-surgery medication use is an important, yet relatively unexplored, element of the BPH patient journey.Rates of medication use through one year were higher following TURP and PVP compared to PUL, and were equivalent at five years.This may indicate that in a real-world setting, TURP and PVP patients could have more advanced disease that doesn't fully respond to the benefits of the selected intervention.The five-year real-world rate of medication usage for PUL in this analysis is similar to the rate demonstrated in the LIFT pivotal trial (10.3% vs. 10.7%LIFT).

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.009
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Other · Consensus signal: Other
Teacher disagreement score0.240
Threshold uncertainty score0.803

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.009
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0000.001
Bibliometrics0.0020.002
Science and technology studies0.0010.000
Scholarly communication0.0030.001
Open science0.0010.002
Research integrity0.0020.002
Insufficient payload (model declined to judge)0.2400.118

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.025
GPT teacher head0.288
Teacher spread0.264 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreOther

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueCanadian Urological Association JournalSame topicHematological disorders and diagnosticsFrench-language works237,207